Cite

HARVARD Citation

    Burmester, G. et al. (2009). Adalimumab safety and mortality rates from global clinical trials of six immune-mediated inflammatory diseases. Annals of the rheumatic diseases. 68 (12), pp. 1863-1869. [Online]. 
  
Back to record